Viking Therapeutics (VKTX) Misses Q4 EPS by 12c

Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.56), $0.12 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Is the global equity rally broadening? UBS weighs in
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue